Palvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Palvella Therapeutics

04/08/2026 14:31

Palvella Therapeutics Inc PVLA.OQ reported a quarterly adjusted loss of $1.52​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -86 cents.  The mean expectation of sixteen analysts for the quarter was for a loss of $1.16 per share. Wall Street expected results to range from $-1.56 to -83 cents per share.
Reported revenue was zero​; analysts expected zero. 
Palvella Therapeutics Inc's reported EPS for the quarter was a loss of $1.52​.
The company reported a quarterly loss of $21.87 million.
Palvella Therapeutics Inc shares had fallen by 7.9% this quarter and gained 34.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 11.8% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Palvella Therapeutics Inc is $225.00, about 37.4% above its last closing price of $140.78
This summary was machine generated from LSEG data August 4 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.16
-1.52
Missed
Mar. 31 2026 
-0.93
-1.20
Missed
Dec. 31 2025 
-0.91
-1.07
Missed
Sep. 30 2025 
-0.84
-1.03
Missed